Captrust Financial Advisors Exelixis, Inc. Transaction History
Captrust Financial Advisors
- $30.9 Billion
- Q2 2024
A detailed history of Captrust Financial Advisors transactions in Exelixis, Inc. stock. As of the latest transaction made, Captrust Financial Advisors holds 34,062 shares of EXEL stock, worth $1.22 Million. This represents 0.0% of its overall portfolio holdings.
Number of Shares
34,062
Previous 32,406
5.11%
Holding current value
$1.22 Million
Previous $768,000
0.39%
% of portfolio
0.0%
Previous 0.0%
Shares
23 transactions
Others Institutions Holding EXEL
# of Institutions
474Shares Held
242MCall Options Held
1.96MPut Options Held
1.39M-
Black Rock Inc. New York, NY33.5MShares$1.2 Billion0.02% of portfolio
-
Vanguard Group Inc Valley Forge, PA29.7MShares$1.06 Billion0.01% of portfolio
-
Farallon Capital Management LLC San Francisco, CA27.1MShares$972 Million2.95% of portfolio
-
Jim Simons Renaissance Technologies LLC | New York, Ny15.2MShares$544 Million0.6% of portfolio
-
State Street Corp Boston, MA12.6MShares$452 Million0.01% of portfolio
About EXELIXIS, INC.
- Ticker EXEL
- Exchange NASDAQ
- Sector Healthcare
- Industry Biotechnology
- Shares Outstandng 321,832,000
- Market Cap $11.5B
- Description
- Exelixis, Inc., an oncology-focused biotechnology company, focuses on the discovery, development, and commercialization of new medicines to treat cancers in the United States. The company's products include CABOMETYX tablets for the treatment of patients with advanced renal cell carcinoma who received prior anti-angiogenic therapy; and COMETRIQ ...